Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 0.79 |
| ▸ | KDR | P35968 | 6/20 | 0.79 |
| ▸ | BRAF | P15056 | 3/20 | 0.69 |
| ▸ | GAK | O14976 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | CIT | O14578 | 2/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.68 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.68 |
| ▸ | STK17B | O94768 | 2/20 | 0.68 |
| ▸ | STK10 | O94804 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | LYN | P07948 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483201 | 1.00 | EGFR (1.00) | EGFRSRCKDRBRAFGAK | |
| Hydrochloric Acid SCHEMBL30133464 | 0.99 | EGFR (0.98) | EGFRSRCKDRBRAFGAK | |
| Hydrochloric Acid SCHEMBL20534441 | 0.99 | EGFR (0.98) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL28696278 | 0.96 | EGFR (0.92) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL29578659 | 0.96 | EGFR (0.92) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL29579338 | 0.92 | EGFR (0.84) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL28700304 | 0.92 | EGFR (0.84) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL23934779 | 0.91 | EGFR (0.83) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL4124144 | 0.90 | EGFR (0.82) | EGFRSRCKDRBRAFGAK | |
| SCHEMBL15879053 | 0.90 | EGFR (0.81) | EGFRSRCKDRBRAFGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924251-A | Gefitinib-linked triazole derivative and preparation method and application thereof | 河南师范大学 | 2024-04-26 | — | — | CN | claimed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | claimed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | claimed |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2020-10-22 | — | — | US | claimed |
| EP-3609875-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | Natco Pharma Limited (IN) | 2020-02-19 | — | — | EP | claimed |
| WO-2018189747-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2018-10-18 | — | — | WO | claimed |
| CN-117924251-A | Gefitinib-linked triazole derivative and preparation method and application thereof | 河南师范大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-117545476-A | EGFR inhibitors for the treatment of head and neck cancer | 纳科制药有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| US-20110034459-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | NATCO PHARMA LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| US-20110034459-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | NATCO PHARMA LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| US-20110028473-A1 | METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS BY ADMINISTERING 6,7-DIALKOXY QUINAZOLINE DERIVATIVES | NATCO PHARMA LTD. (IN) | 2011-02-03 | — | — | US | disclosed |
| US-20110028473-A1 | METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS BY ADMINISTERING 6,7-DIALKOXY QUINAZOLINE DERIVATIVES | NATCO PHARMA LTD. (IN) | 2011-02-03 | — | — | US | disclosed |
| EP-2229369-A1 | 6.7-DIALKOXY OUINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF CANCER RELATED DISORDERS | Natco Pharma Limited (IN) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009090661-A9 | 6.7-DIALKOXY OUINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF CANCER RELATED DISORDERS | NATCO PHARMA LIMITED (IN) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009090661-A1 | 6.7-DIALKOXY OUINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF CANCER RELATED DISORDERS | NATCO PHARMA LIMITED (IN) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034459-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885SRC 92/4885KDR 228/4885 |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | MAP7, NQO2, ABL1 | EGFR 2563/4885SRC 4387/4885KDR 1760/4885 |
| US-20110028473-A1 | METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS BY ADMINISTERING 6,7-DIALKOXY QUINAZOLINE DERIVATIVES | ERBB2, BRCA1, EGFR | EGFR 3/4885SRC 955/4885KDR 872/4885 |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | PAH, NQO2, MAP7 | EGFR 2948/4885SRC 4680/4885KDR 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.